Episode Description from the Publisher
Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Get Free Summaries →
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
Get summaries like this every morning.
Free AI-powered recaps of Derms on Drugs and your other favorite podcasts, delivered to your inbox.
Get Free Summaries →
Free forever for up to 3 podcasts. No credit card required.